May is ALS Awareness Month. Learn more about what you can do to end ALS with MDA.

About Us

Our mission is to empower people living with neuromuscular diseases to live longer, more independent lives.

Marathon Pharmaceuticals Presents Analyses at AAN of a Phase III Clinical Study of Deflazacort in Patients with Duchenne Muscular Dystrophy (DMD)

Investigational Drug Deflazacort Has Fast Track Status, Orphan Drug Designation and Rare Pediatric Disease Designation for DMD from FDA